Skip to content

Helix Life Science Digest

Welcome to the Helix life science digest! Helix, a leader in population genomics and precision health, started 2025 announcing three new partnerships highlighting the rapid growth of the Helix Research Network (HRN), and with the publication of innovative translational research providing deep analytics and insights from genetic and real-world data across our network.

This quarterly newsletter will provide a comprehensive overview of network-wide updates and insights, designed to keep you informed on achievements, offerings, research insights, events, and much more across Helix and life sciences!

Connect with us

Data and Cohort updates (through Q1 2025):

26K GLP-1 Agonist Patients

Helix announced the launch of the largest GLP-1 clinico-genomic dataset in the world, encompassing data and insights from over 26K treated patients across the US

23K Autoimmune Patients

Helix announced the launch of an Autoimmune cohort, comprised of over 23k patients diagnosed with I&I conditions and inclusive of full lab data

Partnerships:

Helix-Komodo Health partnership to further enrich Helix's linked clinico-genomic datasets for research and life science partners. This partnership will add insights derived from medical, pharmacy and mortality data from Komodo's Healthcare Map®, the industry's most robust and precise view of longitudinal de-identified patient-level insights.

TriHealth, Parkview Health, and Rochester Regional Health have joined the Helix Research Network. Each health system has committed to enroll 100,000 participants, ultimately adding at least 300,000 new participants to the largest and fastest growing precision clinical research network in the world.

Research Roundup

1
2
01

GCK Variant Research

Helix researchers recently published a study in Nature which conducted a population-level assessment showing secondary complications in individuals with pathogenic and glucose-elevating GCK variants and T2D and suggests that genotyping for these variants should be considered in a precision medicine approach for T2D treatment and prevention.

02

ACMG 2025 Posters

Helix Researchers unveiled new clinical research from the Helix Research NetworkTM (HRN) and its partners at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles, CA showcasing how genomic screening can not only accurately identify high-risk individuals but also improve adherence to recommended care. The novel research goes a step further to demonstrate how real-world evidence can ultimately enable precision medicine through personalized monitoring plans based on individual risk and improve and automate the interpretation of genetic variations for increased accuracy. Take a look at our latest research posters from ACMG.

Content Corner

Despite semaglutide’s proven efficacy in diabetes and obesity treatment, there is significant heterogeneity in weight loss experienced by patients and genetic factors remain unclear. Helix researcher, Dr. Matt Levy, recently presented groundbreaking analysis using Helix data to identify key metabolic and genetic factors associated with weight loss in semaglutide, evaluated the impact of established BMI polygenic risk scores (PGS), and more.

Upcoming Events

European Society of Human Genetics (May 24 - May 27, 2025)

Milan, Italy

BIO Convention (June 16 - 19, 2025)

Boston, MA

Festival of Genomics and Biodata (June 24-25, 2025)

Boston, MA